IP Library › Granted Patent US 12,715,927
Granted Patent B2
US 12,715,927 · App. 18/056,411 · Granted Aug 25, 2026

Monospecific antibodies that antagonize leptin receptor

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,715,927
App. No.
18/056,411
Filed
Nov 17, 2022
Granted
Aug 25, 2026
Kind
B2
Art Unit
1674
USPC
424/139.1
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 1, 2026
From: GROMADA, JESPER; STEVIS, PANAYIOTIS; ALTAREJOS, JUDITH
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 074251/0782 →
Continuity (4)
Continuation 16736760 · Jan 7, 2020
Division 15807426 · Nov 8, 2017
Provisional Application 62419062 · Nov 8, 2016
Related Publication 20230235068A1 · Jul 27, 2023
References Cited (400)
US 4596556A · Morrow et al. · 1986 [cited by applicant]
US 4790824A · Morrow et al. · 1988 [cited by applicant]
US 4941880A · Burns · 1990 [cited by applicant]
US 4946778A · Ladner et al. · 1990 [cited by applicant]
US 5064413A · McKinnon et al. · 1991 [cited by applicant]
US 5312335A · McKinnon et al. · 1994 [cited by applicant]
US 5383851A · McKinnon et al. · 1995 [cited by applicant]
US 5399163A · Peterson et al. · 1995 [cited by applicant]
US 5717073A · Wijdenes et al. · 1998 [cited by applicant]
US 5932448A · Tso et al. · 1999 [cited by applicant]
US 5965521A · Stephens et al. · 1999 [cited by applicant]
US 6005080A · Snodgrass et al. · 1999 [cited by applicant]
US 6096002A · Landau · 2000 [cited by applicant]
US 6096506A · Lee et al. · 2000 [cited by applicant]
US 6129914A · Weiner et al. · 2000 [cited by applicant]
US 6329511B1 · Vasquez et al. · 2001 [cited by applicant]
US 6380363B1 · Tartaglia et al. · 2002 [cited by applicant]
US 6620135B1 · Weston et al. · 2003 [cited by applicant]
US 6977240B1 · Tartaglia et al. · 2005 [cited by applicant]
US 7067472B1 · Feng et al. · 2006 [cited by applicant]
US 7067477B2 · MacLeod · 2006 [cited by applicant]
US 7183254B2 · DePaoli et al. · 2007 [cited by applicant]
US 7261893B2 · Veldman et al. · 2007 [cited by applicant]
US 7294754B2 · Poueymirou et al. · 2007 [cited by applicant]
US 7307142B2 · Gertler et al. · 2007 [cited by applicant]
US 7320789B2 · Aghahanian et al. · 2008 [cited by applicant]
US 7521048B2 · Gliniak et al. · 2009 [cited by applicant]
US 7524937B2 · Carter et al. · 2009 [cited by applicant]
US 7575878B2 · Tavernier et al. · 2009 [cited by applicant]
US 7576259B2 · Poueymirou et al. · 2009 [cited by applicant]
US 7632499B2 · Davies et al. · 2009 [cited by applicant]
US 7635760B2 · Han et al. · 2009 [cited by applicant]
US 7659442B2 · Poueymirou et al. · 2010 [cited by applicant]
US 7807159B2 · Chin et al. · 2010 [cited by applicant]
US 7863240B2 · Ilan et al. · 2011 [cited by applicant]
US 7888486B2 · Walsh et al. · 2011 [cited by applicant]
US 8017634B2 · Sinclair et al. · 2011 [cited by applicant]
US 8318666B2 · DePaoli et al. · 2012 [cited by applicant]
US 8697396B2 · Dall'Acqua et al. · 2014 [cited by applicant]
US 8840894B2 · Stitt et al. · 2014 [cited by applicant]
US 8846724B2 · Sinclair et al. · 2014 [cited by applicant]
US 8871209B2 · Stitt et al. · 2014 [cited by applicant]
US 8969291B2 · Ilan et al. · 2015 [cited by applicant]
US 9221902B2 · Smider et al. · 2015 [cited by applicant]
US 9260515B2 · Stitt et al. · 2016 [cited by applicant]
US 9332742B2 · Mcwhirter et al. · 2016 [cited by applicant]
US 9334331B2 · Igawa et al. · 2016 [cited by applicant]
US 9421257B2 · Ilan et al. · 2016 [cited by applicant]
US 9718881B2 · Gromada et al. · 2017 [cited by applicant]
US 9890212B2 · Stitt et al. · 2018 [cited by applicant]
US 10023644B2 · Gromada et al. · 2018 [cited by applicant]
US 10253102B2 · Gromada et al. · 2019 [cited by applicant]
US 10400036B2 · Stitt et al. · 2019 [cited by applicant]
US 10421807B2 · Gonzales et al. · 2019 [cited by applicant]
US 10526403B2 · Gromada et al. · 2020 [cited by applicant]
US 10550192B2 · Gromada et al. · 2020 [cited by applicant]
US 10618968B2 · Gromada et al. · 2020 [cited by applicant]
US 10934249B2 · Pordy et al. · 2021 [cited by applicant]
US 11248044B2 · Donahue et al. · 2022 [cited by applicant]
US 11535675B2 · Gromada et al. · 2022 [cited by applicant]
US 11608381B2 · Gromada et al. · 2023 [cited by applicant]
US 11834500B2 · Gromada et al. · 2023 [cited by applicant]
US 12275792B2 · Gromada et al. · 2025 [cited by applicant]
US 12371503B2 · Gromada et al. · 2025 [cited by applicant]
US 20040202652A1 · Karsenty et al. · 2004 [cited by applicant]
US 20040253242A1 · Bowdish et al. · 2004 [cited by applicant]
US 20060068429A1 · Bailleul et al. · 2006 [cited by applicant]
US 20070178095A1 · Smith et al. · 2007 [cited by applicant]
US 20080078000A1 · Poueymirou et al. · 2008 [cited by applicant]
US 20090148436A1 · Lavallie et al. · 2009 [cited by applicant]
US 20090234106A1 · Han et al. · 2009 [cited by applicant]
US 20100166764A1 · Sayers et al. · 2010 [cited by applicant]
US 20100260772A1 · Karsenty · 2010 [cited by applicant]
US 20110092417A1 · Artymiuk et al. · 2011 [cited by applicant]
US 20110293630A1 · Stitt et al. · 2011 [cited by applicant]
US 20120204278A1 · Bradley et al. · 2012 [cited by applicant]
US 20120258073A1 · Gerdes et al. · 2012 [cited by applicant]
US 20130122007A1 · Stitt et al. · 2013 [cited by applicant]
US 20140134162A1 · Stavenhagen et al. · 2014 [cited by applicant]
US 20140171623A1 · Dall'Acqua et al. · 2014 [cited by applicant]
US 20140243504A1 · Davis et al. · 2014 [cited by applicant]
US 20180037648A1 · Ilan et al. · 2018 [cited by applicant]
US 20180127508A1 · Gromada et al. · 2018 [cited by applicant]
US 20190002569A1 · Belaid-Choucair et al. · 2019 [cited by applicant]
US 20190185562A1 · Gromada et al. · 2019 [cited by applicant]
US 20190309079A1 · Gromada · 2019 [cited by applicant]
US 20200031946A1 · Gromada et al. · 2020 [cited by applicant]
US 20200123264A1 · Gromada et al. · 2020 [cited by applicant]
US 20220098313A1 · Oral et al. · 2022 [cited by applicant]
US 20220112293A1 · Gromada et al. · 2022 [cited by applicant]
US 20220280641A1 · Gromada et al. · 2022 [cited by applicant]
US 20230235068A1 · Gromada et al. · 2023 [cited by applicant]
US 20240158497A1 · Gromada et al. · 2024 [cited by applicant]
US 20240247071A2 · Altarejos et al. · 2024 [cited by applicant]
US 20250051465A1 · Gromada et al. · 2025 [cited by applicant]
US 20250320301A1 · Gromada et al. · 2025 [cited by applicant]
AU 2004201496C1 · 2018 [cited by applicant]
CN 107760761 · 2018 [cited by applicant]
EP 981365B1 · 2004 [cited by applicant]
EP 885299B1 · 2005 [cited by applicant]
EP 0730606B1 · 2005 [cited by applicant]
EP 0879286B1 · 2008 [cited by applicant]
EP 1619250B1 · 2009 [cited by applicant]
EP 1444516B1 · 2010 [cited by applicant]
EP 1019432B1 · 2012 [cited by applicant]
EP 2219031B1 · 2013 [cited by applicant]
EP 2780368 · 2014 [cited by applicant]
EP 2649184B1 · 2015 [cited by applicant]
EP 3298889A1 · 2018 [cited by applicant]
EP 2989894B1 · 2020 [cited by applicant]
EP 3362477B1 · 2022 [cited by applicant]
JP 1991219894 · 1991 [cited by applicant]
WO WO1996005309 · 1996 [cited by applicant]
WO WO199608510 · 1996 [cited by applicant]
WO WO1997019952 · 1997 [cited by applicant]
WO WO1997025425 · 1997 [cited by applicant]
WO WO199726272 · 1997 [cited by applicant]
WO WO199726335 · 1997 [cited by applicant]
WO WO199726370 · 1997 [cited by applicant]
WO WO199726523 · 1997 [cited by applicant]
WO WO199727286 · 1997 [cited by applicant]
WO WO199741263 · 1997 [cited by applicant]
WO WO199822128A1 · 1998 [cited by applicant]
WO WO199848831 · 1998 [cited by applicant]
WO WO200236789 · 2002 [cited by applicant]
WO WO200266630 · 2002 [cited by applicant]
WO WO2005049655 · 2005 [cited by applicant]
WO WO2006053883 · 2006 [cited by applicant]
WO WO2010070094 · 2010 [cited by applicant]
WO WO2011004192 · 2011 [cited by applicant]
WO WO2011097603 · 2011 [cited by applicant]
WO WO2011130499A1 · 2011 [cited by applicant]
WO WO2012141798 · 2012 [cited by applicant]
WO WO2012148873 · 2012 [cited by applicant]
WO WO2013022782 · 2013 [cited by applicant]
WO WO2013184761 · 2013 [cited by applicant]
WO WO2014043361A1 · 2014 [cited by applicant]
WO WO2015124588 · 2015 [cited by applicant]
WO WO2016039796A2 · 2016 [cited by applicant]
WO WO2016168613A1 · 2016 [cited by applicant]
WO WO2017066204A1 · 2017 [cited by applicant]
WO WO2018089532 · 2018 [cited by applicant]
WO WO2019195796 · 2019 [cited by applicant]
WO WO2020131910A1 · 2020 [cited by applicant]
WO WO2022060827A3 · 2022 [cited by applicant]
Sandhu et al, 1992. Critical Reviews in Biotechnology. 12(5/6): 437-462. [cited by examiner]
“A Study to Examine the Safety, Tolerability and Biological Effects of REGN4461 in Healthy Volunteers [ClinicalTrials.gov posting, identifier NCT03530514]. Accessed May 21, 2018.” [cited by applicant]
“Expanded Access to REGN4461 for Patients With 1) Generalized Lipodystrophy, 2) Partial Lipodystrophy or 3) Monogenic Obesity Due to LEP or LEPR Loss of Function [ClinicalTrials.gov posting, identifier NCT04710056]. Acc… [cited by applicant]
“Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients with Generalized Lipodystrophy [ClinicalTrials.gov posting, identifier NCT04159415]. Accessed Nov. 12, 2019.” [cited by applicant]
Accession No. NP_001003679.1 to: Protein [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; [2019]—Accession No. NP_001003679.1, “Leptin Receptor Isoform 3 Precu… [cited by applicant]
Accession No. NP_002175.2 to: Protein [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; [2019]—Accession No. NP_002175.2, “Interleukin-6 Receptor Subunit Beta I… [cited by applicant]
Ajluni et al. (2017) “Spectrum of Disease Associated with Partial Lipodystrophy: Lessons from a Trial Cohort”, Clin Endocrinol (Oxf), 86(5): 698-707. [cited by applicant]
Akinci et al. (2017) “Clinical Presentations, Metabolic Abnormalities and End-Organ Complications in Patients with Familial Partial Lipodystrophy”, Metabolism—Clin and Exp., 72: 109-119. [cited by applicant]
Akinci et al. (2018) “Phenotypic and Genetic Characteristics of Lipodystrophy: Pathophysiology, Metabolic Abnormalities, and Comorbidities”, Curr Diab Rep., 18(12):143, 1-12. [cited by applicant]
Akinci et al. (2018) “Renal Complications of Lipodystrophy: A Closer Look at the Natural History of Kidney Disease”, Clin Endocrinol (Oxf), 89(1):65-75. [cited by applicant]
Akinci et al. (2020) “Adipose Tissue, Appetite, and Obesity, Mechanisms and Treatment of Obesity in Humans, The Treatment of Partial Lipodystrophy in the Setting of Neutralizing Antibody Against Metreleptin with Leptin … [cited by applicant]
Akinci et al. (2020) “The Complicated Clinical Course in a Case of Atypical Lipodystrophy After Development of Neutralizing Antibody to Metreleptin: Treatment with Setmelanotide”, Endocrinol Diabetes Metab Case Rep., 1-… [cited by applicant]
Altschul (1991) “Amino Acid Substitution Matrices from an Information Theoretic Perspective”, J. Mol. Biol., 219: 555-565. [cited by applicant]
Altschul (1993) “A Protein Alignment Scoring System Sensitive at all Evolutionary Distances”, J. Mol. Evol., 36:290-300. [cited by applicant]
Altschul et al. (2005) “Protein Database Searches Using Compositionally Adjusted Substitution Matrices”, FEBS J., 272(20): 5101-5109. [cited by applicant]
Anonymus (2019) “Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patient with Generalized Lipodystrophy”, Full Text View, ClinicalTrials.gov, Nov. 12, 2019, 10 pages. [cited by applicant]
Anthony (2008) “Nutrition Screening Tools for Hospitalized Patients”, Nutr. Clin. Pract. 23: 373-382. [cited by applicant]
Aslam et al. (2013) “Acquired Generalized Lipodystrophy Associated with Peripheral Tcell Lymphoma with Cutaneous Infiltration”, International J. Dermatol., 54: 827-829. [cited by applicant]
Baca et al. (1997) “Antibody Humanization Using Monovalent Phage Display,” J Biol Chem., 272(16): 10678-10684. [cited by applicant]
Bahrenberg et al. (2002) “Identification of the Critical Sequence Elements in the Cytoplasmic Domain of Leptin Receptor Isoforms Required for Janus Kinase/Signal Transducer and Activator of Transcription Activation by R… [cited by applicant]
Barbas (1995) “Synthetic Human Antibodies”, Nat Med., 1(8): 837-839. [cited by applicant]
Barr et al. (1999) “Subcellular Localization and Internalization of the Four Human Leptin Receptor Isoforms”, J Biol Chem., 274(30): 21416-21424. [cited by applicant]
Barsh & Schwartz (2002) “Genetic Approaches to Studying Energy Balance: Perception and Integration”, Nat Rev Genet., 3(8): 589-600. [cited by applicant]
Bates & Myers (2003) “The Role of Leptin Receptor Signaling in Feeding and Neuroendocrine Function”, TRENDS in Endocrinology and Metabolism, 14(10): 447-452. [cited by applicant]
Bates et al. (2003) “STAT3 Signaling is Required for Leptin Regulation of Energy Balance but not Reproduction”, Nature 421: 856-859. [cited by applicant]
Bendig (1995) “Humanization of Rodent Monoclonal Antibodies by CDR Grafting”, Method3: A Companion to Methods in Enzymology, 8: 83-93. [cited by applicant]
Bingham et al. (2008) “Predictors of Acquired Lipodystrophy in Juvenile-Onset Dermatomyositis and a Gradient of Severity”, Medicine (Baltimore), 87(2): 70-86. [cited by applicant]
Bjornholm et al. (2007) “Mice Lacking Inhibitory Leptin Receptor Signals are Lean with Normal Endocrine Function”, J. Clin. Invest., 117: 1354-1360. [cited by applicant]
Boersma and Pluckthun (2011) “DARPins and Other Repeat Protein Scaffolds: Advances in Engineering and Applications”, Curr. Opin. Biotechnol., 22: 849-857. [cited by applicant]
Bolan et al. (2002) “Intensive, Long-Term Plasma Exchange Therapy for Severe Hypertriglyceridemia in Acquired Generalized Lipoatrophy”, J Clin Endocrinol Metab., 87(1): 380-384. [cited by applicant]
Brennan et al. (1985) “Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G1 Fragments,” Science, 229: 81-83. [cited by applicant]
Brown et al. (2016) “Lymphoma in Acquired Generalized Lipodystrophy”, Leuk Lymphoma, 57(1): 45-50. [cited by applicant]
Brown et al. (2018) “Long-Term Effectiveness and Safety of Metreleptin in the Treatment of Patients with Generalized Lipodystrophy”, Endocrine, 60(3): 479-489. [cited by applicant]
Bülbül et al. (2001) “Acute Pancreatitis in a Patient with Partial Lipodystrophy and Membranoproliferative Glomerulonephritis”, Nephrol Dial Transplant., 16(9): 1930-1931. [cited by applicant]
Carpenter et al. (1998) “Enhancing Leptin Response by Preventing SH2-containing Phosphate 2 Interaction with Ob Receptor”, Proc. Natl. Acad. Sci. USA, 95: 6061-6066. [cited by applicant]
Carpenter et al. (2000) “Non-Fc Receptor-Binding Humanized Anti-CD3 Antibodies Induce Apoptosis of Activated Human T Cells,” J Immunol. 165(11): 6205-16213. [cited by applicant]
Carter (2001) “Bispecific Human IgG by Design”, J Immunol Meth., 248: 7-15. [cited by applicant]
Casset et al. (2003) “A Peptide Mimetic of an Anti-CD4 Monoclonal Antibody by Rational Design”, Biochemical and Biophysical Research Communications, 307: 198-205. [cited by applicant]
Ceddia (2005) “Direct Metabolic Regulation in Skeletal Muscle and Fat Tissue by Leptin: Implications for Glucose and Fatty Acids Homeostasis”, Int J Obes., 29(10): 1175-1183. [cited by applicant]
Chen et al. (1996) “Evidence That the Diabetes Gene Encodes the Leptin Receptor: Identification of a Mutation in the Leptin Receptor Gene in db/db Mice”, Cell, 84(3): 491-495. [cited by applicant]
Cheung (2014) “A Pegylated Leptin Antagonist Ameliorates CKD-Associated Cachexia in Mice”, J Am Soc Nephrol., 25(1): 119-128. [cited by applicant]
Chothia et al. (1987) “Canonical Structures for the Hypervariable Regions of Immunoglobulins”, J. Mol. Biol., 196: 901-917. [cited by applicant]
Chothia et al. (1989) “Conformations of Immunoglobulin Hypervariable Regions”, Nature, 342: 877-883. [cited by applicant]
Conrath et al. (2001) “Camel Single-Domain Antibodies as Modular Building Units in Bispecific and Bivalent Antibody Constructs”, J Biol Chem., 276(10): 7346-7350. [cited by applicant]
Coppari & Bjørbæk (2012) “The Potential of Leptin for Treating Diabetes and Its Mechanism of Action”, Nat Rev Drug Discov., 11(9): 692-708. [cited by applicant]
Cron et al. (2016) “The Role of gp130 Receptor Cytokines in The Regulation of Metabolic Homeostasis”, Journal of Experimental Biology, 219(2): 259-265. [cited by applicant]
De Bruin et al. (1999) “Selection of High-Affinity Phage Antibodies from Phage Display Libraries”, Nat Biotech. 17: 397-399. [cited by applicant]
Dechiara et al. (2009) “VelociMouse: Fully ES Cell-Derived F0-Generation Mice Obtained from the Injection of ES Cells into Eight-Cell-Stage Embryos”, Meth Mol Biol., 530: 311-24. [cited by applicant]
Dechiara et al. (2010) “Producing Fully ES Cell-Derived Mice from Eight-Cell Stage Embryo Injections”, Meth Enzymol., 476: 285-94. [cited by applicant]
Dembo et al. (1994) “Limit Distribution of Maximal Non-Aligned Two-Sequence Segmental Score”, Ann. Prob., 22(4): 2022-2039. [cited by applicant]
Desmyter et al. (2001) “Antigen Specificity and High Affinity Binding Provided by One Single Loop of a Camel Single-Domain Antibody”, J Biol Chem., 276(28): 26285-26290. [cited by applicant]
Detsky et al. (1987) “What is Subjective Global Assessment of Nutritional Status?” J Parent Enteral Nutr., 11(1): 8-13. [cited by applicant]
Dewall et al. (2008) “Collective and Individual Functions of Leptin Receptor Modulated Neurons Controlling Metabolism and Ingestion”, Endocrinology, 149(4): 1773-1785. [cited by applicant]
Eldin et al. (2020) “Healthcare Delivery and Education, Expanding Clinical Considerations for Patient Testing and Care—Pain is a Major Driver of Quality of Life and Psychoemotional Health in Lipodystrophy Syndromes”, Jo… [cited by applicant]
Everts et al. (2002) “Selective Intracellular Delivery of Dexamethasone into Activated Endothelial Cells Using an E-Selection-Directed Immunoconjugate”, J Immunol., 168: 883-889. [cited by applicant]
Fearon et al. (2011) “Definition and Classification of Cancer Cachexia: An International Consensus”, Lancet Oncol., 12: 489-495. [cited by applicant]
Febbraio (2007) “gp130 Receptor Ligands as Potential Therapeutic Targets for Obesity”, Journal of Clinical Investigation, 117(4): 841-849. [cited by applicant]
Ferguson et al. (1999) “Validation of a Malnutrition Screening Tool for Patients Receiving Radiotherapy”, Australas Radio., 43: 325-327. [cited by applicant]
Foote and Winter (1992) “Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops”, J Mol Biol., 224: 487-499. [cited by applicant]
Foss-Freitas, et al. (2020) “Diagnostic Strategies and Clinical Management of Lipodystrophy”, Expert Rev Endocrinol Metab, 15(2): 95-114. [cited by applicant]
Foster, et al. (2003) “Body Weight Regulation by Selective MC4 Receptor Agonists and Antagonists”, Ann N.Y. Acad Sci., 994: 103-110. [cited by applicant]
Franceschini, et al. (1995) “Pre-B Acute Lymphoblastic Leukemia in a Patient with Partial Lipodystrophy and Acanthosis Nigricans”, Panminerva Med., 37(4): 248-251. [cited by applicant]
Garg (2000) “Gender Differences in the Prevalence of Metabolic Complications in Familial Partial Lipodystrophy (Dunnigan Variety)”, J Clin Endocrinol Metab., 85(5): 1776-1782. [cited by applicant]
Ge et al. (2018) “Leptin in Depression: A Potential Therapeutic Agent”, Cell Death & Disease, 9(11): 1096, 10 pages. [cited by applicant]
Gibellini et al. (1998) “Extracellular HIV-1 Tat Protein Induces the Rapid Ser133 Phosphorylation and Activation of CREB Transcription Factor in Both Jurkat Lymphoblastoid T Cells and Primary Peripheral Blood Mononuclea… [cited by applicant]
Gish et al. (1993) “Identification of Protein Coding Regions by Database Similarity Search”, Nature Genet., 3: 266-272. [cited by applicant]
Greenfield et al. (2009) “Modulation of Blood Pressure by Central Melanocortinergic Pathways”, N Engl J Med., 360: 44-52. [cited by applicant]
Gromada et al. (2017) “New Isolated Antibody That Binds Human Leptin Receptor (LEPR) and Activates LEPR Signaling Used to Treat Disease Associated with or Caused by Leptin Deficiency or Leptin Resistance e.g. Lipodystro… [cited by applicant]
Hall et al. (1978) “Generalised Lipodystrophy, Scleroderma, and Hodgkin's Disease”, Arch Intern Med., 138(8): 1303-1304. [cited by applicant]
Hancock et al. (1994) “SIMPLE34: An Improved and Enhanced Implementation for VAX and Sun Computers of the SIMPLE Algorithm for Analysis of Clustered Repetitive Motifs in Nucleotide Sequences”, Comput. Appl. Biosci., 10(… [cited by applicant]
Handelsman et al. (2013) “The Clinical Approach to the Detection of Lipodystrophy—An AACE Consensus Statement”, Endocr Pract., 19(1): 107-16. [cited by applicant]
Haque et al. (2002) “Post-Mortem Findings in Familial Partial Lipodystrophy”, Dunnigan Variety. Diabet Med., 19(12): 1022-1025. [cited by applicant]
He et al. (1998) “Humanization and Pharmacokinetics of a Monoclonal Antibody with Specificity for Both E- and P-Selectin”, J Immunol., 160: 1029-1035. [cited by applicant]
Hegele (2001) “Premature Atherosclerosis Associated with Monogenic Insulin Resistance”, Circulation, 103(18): 2225-2229. [cited by applicant]
Henikoff et al. (1992) “Amino Acid Substitution Matrices from Protein Blocks”, Proc. Natl. Acad. Sci. USA, 89: 10915-10919. [cited by applicant]
Hoogenboom and Chames (2000) “Natural and Designer Binding Sites Made by Phage Display Technology”, Immunol Today, 21(8): 371-377. [cited by applicant]
Hsing and Bishop (1999) “Requirement for Nuclear Factor-kB Activation by a Distinct Subset of CD40-Mediated Effector Functions in B Lymphocytes”, J Immunol., 162: 2804-2811. [cited by applicant]
Hudson and Kortt (1999) “High Avidity scFv Multimers; Diabodies and Triabodies”, J Immunol Meth., 231: 177-189. [cited by applicant]
Hukshorn et al. (2003) “Pegylated Human Recombinant Leptin (PEG-OB) Causes Additional Weight Loss in Severely Energy-Restricted, Overweight Men”, Am J Clin Nutr., 77: 771-776. [cited by applicant]
International Search Report and Written Opinion for PCT/US2019/066908 mailed Mar. 25, 2020. [cited by applicant]
Janoschek et al. (2006) “gp130 Signaling in Proopiomelanocortin Neurons Mediates the Acute Anorectic Response to Centrally Applied Ciliary Neurotrophic Factor”, PNAS, 103(28): 10707-10712. [cited by applicant]
Javor et al. (2004) “Proteinuric Nephropathy in Acquired and Congenital Generalized Lipodystrophy: Baseline Characteristics and Course During Recombinant Leptin Therapy”, J Clin Endocrinol Metab., 89(7): 3199-3207. [cited by applicant]
Kabat (1978) “The Structural Basis for Antibody Complementary”, Adv. Prot. Chem., 32: 1-75. [cited by applicant]
Kabat et al. (1977) “Unusual Distributions of Amino Acids in Complementarity-Determining (Hypervariable) Segments of Heavy and Light Chains of Immunoglobulins and Their Possible Roles in Specificity of Antibody-Combinin… [cited by applicant]
Kaithamana et al. (1999) “Induction of Experimental Autoimmune Graves' Disease in BALB/c Mice”, J Immunol., 163: 5157-5164. [cited by applicant]
Karlin et al. (1990) “Methods for Assessing the Statistical Significance of Molecular Sequence Features by Using General Scoring Schemes”, Proc. Natl. Acad. Sci. USA, 87: 2264-2268. [cited by applicant]
Karlin et al. (1993) “Applications and Statistics for Multiple High-Scoring Segments in Molecular Sequences”, Proc. Natl. Acad. Sci. USA, 90: 5873-5877. [cited by applicant]
Kawahara et al. (2003) “Bypassing Antibiotic Selection: Positive Screening of Genetically Modified Cells with an Antigen-Dependent Proliferation Switch”, Nucleic Acids Research, 31(No. 7 e32): 1-8. [cited by applicant]
Kievet et al. (2013) “Chronic Treatment with a Melanocortin-4 Receptor Agonist Causes Weight Loss, Reduces Insulin Resistance, and Improves Cardiovascular Function in Diet-Induced Obese Rhesus Macaques”, Diabetes, 62: 4… [cited by applicant]
Kruizenga et al. (2005) “Development and Validation of a Hospital Screening Tool for Malnutriton: The Short Nutritional Assessment Questionnaire (SNAQ)”, Clin Nutr 24: 75-82. [cited by applicant]
Kruizenga et al. (2010) “The SNAQRC, An Easy Traffic Light System as a First Step in the Recognition of Undernutrition in Residential Care”, J Nutr Health Aging, 14(2): 83-89. [cited by applicant]
Kühnen et al. (2016) “Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist”, N Engl J Med, 375: 240-246. [cited by applicant]
Kyratsous et al. (2015) “Reply to Dimitrov et al.: VelociSuite Technologies are a Foundation for Rapid Therapeutic Antibody Development”, PNAS 112(37): E5116. [cited by applicant]
Lambert et al. (2001) “Ciliary Neurotrophic Factor Activates Leptin-like Pathways and Reduces Body Fat, Without Cachexia or Rebound Weight Gain, Even in Leptin-Resistant Obesity”, PNAS, 98(8): 4652-4657. [cited by applicant]
Le Doussal et al. (1991) “Enhanced In Vivo Targeting of an Asymmetric Bivalent Hapten to Double-Antigen-Positive Mouse B Cells with Monoclonal Antibody Conjugate Cocktails”, J Immunol., 146(1): 169-175. [cited by applicant]
Liu et al. (2010) “Acute Administration of Leptin Produces Anxiolytic-like Effects: A Comparison with Fluoxetine”, Psychopharmacology, Springer, Berlin, DE, 207(4): 535-545. [cited by applicant]
Lloyd et al. (2009) “Modeling the Human Immune Response: Performance of a 10(11) Human Antibody Repertoire Against a Broad Panel of Therapeutically Relevant Antigens”, Protein Engineering & Selection, 22(3): 159-168. [cited by applicant]
Lüdtke, et al. (2005) “Hepatic Steatosis in Dunnigan-Type Familial Partial Lipodystrophy”, Am J Gastroenterol., 100(10): 2218-2224. [cited by applicant]
Maccallum et al. (1996) “Antibody-Antigen Interactions: Contact Analysis and Binding Site Topography”, J. Mol. Biol., 262: 732-745. [cited by applicant]
Mack et al. (1995) “A Small Bispecific Antibody Construct Expressed as a Functional Single-Chain Molecule with High Tumor Cell Cytotoxicity”, Proc Natl Acad Sci., 92: 7021-7025. [cited by applicant]
Madden et al. (1996) “Applications of Network BLAST Server”, Meth. Enzymol., 266: 131-141. [cited by applicant]
Malecki et al. (2002) “Molecular Immunolabeling with Recombinant Single-Chain Variable Fragment (scFv) Antibodies Designed with Metal-Binding Domains”, Proc Natl Acad Sci., 99(1): 213-218. [cited by applicant]
Marks & Cone (2001) “Central Melanocortins and The Regulation of Weight During Acute and Chronic Disease”, Recent Prog Horm Res., 56: 359-375. [cited by applicant]
Marsh et al. (1999) “Effects of Neuropeptide Y Deficiency on Hypothalamic Agouti-Related Protein Expression and Responsiveness to Melanocortin Analogues”, Brain Research, 848: 66-77. [cited by applicant]
Marsh et al. (1999) “Response of Melanocortin-4 Receptor-Deficient Mice to Anorectic and Orexigenic Peptides”, Nature Genetics, 21: 119-122. [cited by applicant]
Martin et al. (1991) “Molecular Modeling of Antibody Combining Sites”, Methods Enzymol., 203: 121-153. [cited by applicant]
Mendez et al. (1997) “Functional Transplant of Megabase Human Immunoglobulin Loci Recapitulates Human Antibody Response in Mice”, Nat Gen., 15: 146-156. [cited by applicant]
Menne et al. (2000) “A Comparison of Signal Sequence Prediction Methods Using a Test Set of Signal Peptides”, Bioinformatics, 16(8): 741-742. [cited by applicant]
Meyaard et al. (1997) “LAIR-1, a Novel Inhibitory Receptor Expressed on Human Mononuclear Leukocytes”, Immunity, 7: 283-290. [cited by applicant]
Misra et al. (2003) “Clinical Features and Metabolic Derangements in Acquired Generalized Lipodystrophy: Case Reports and Review of the Literature”, Medicine (Baltimore), 82(2): 129-146. [cited by applicant]
Misra et al. (2004) “Clinical Features and Metabolic and Autoimmune Derangements in Acquired Partial Lipodystrophy: Report of 35 Cases and Review of the Literature”, Medicine (Baltimore), 83(1): 18-34. [cited by applicant]
Mori et al. (2004) “Socs3 Deficiency in the Brain Elevates Leptin Sensitivity and Confers Resistance to Diet-Induced Obesity”, Nature Medicine, 10(7): 739-743. [cited by applicant]
Morris & Rui (2009) “Recent Advances in Understanding Leptin Signaling and Leptin Resistance”, Am J Physiol Endocrinol Metab., 297(6): E1247-59. [cited by applicant]
Morrison (1985) “Transfectomas Provide Novel Chimeric Antibodies”, Science 229: 1202-1207. [cited by applicant]
Murphy et al. (2014) “Mice with Megabase Humanization of their Immunoglobulin Genes Generate Antibodies as Efficiently as Normal Mice”, PNAS, 111(14): 5153-5158. [cited by applicant]
Neelemaat et al. (2008) “Screening Malnutrition in Hospital Outpatients. Can the SNAQ Malnutrition Screening Tool Also be Applied to this Population?” Clin Nutr 27:439-446. [cited by applicant]
Oral & Chan (2010) “Rationale for Leptin-Replacement Therapy for Severe Lipodystrophy”, Endocr Pract., 16(2): 324-333. [cited by applicant]
Oral et al. (2019) “Long-Term Effectiveness and Safety of Metreleptin in the Treatment of Patients with Partial Lipodystrophy”, Endocrine, 64(3): 500-511. [cited by applicant]
O'Sullivan et al. (2007) “Cytokine Receptor Signaling Through the Jak-Stat-Socs Pathway in Disease,” Mol. Immunol., 44(10): 2497-2506. [cited by applicant]
Ottaway et al. (2015) “Diet-Induced Obese Mice Retain Endogenous Leptin Action”, Cell Metabolism, 21:877-882. [cited by applicant]
Özen, et al.(2020) “Current Diagnosis, Treatment and Clinical Challenges in the Management of Lipodystrophy Syndromes in Children and Young People”, J Clin Res Pediatr Endocrinol, 12(1):17-28. [cited by applicant]
Paul (1993) “Fundamental Immunology”, 3rd Edition, Laboratory of Immunology National Institute of Allergy and Infection Diseases National Institutes of Health, pp. 292-295. [cited by applicant]
PCT International Search Report and Written Opinion for International application No. PCT/US2018/066075 mailed Feb. 25, 2019. [cited by applicant]
Pearson (2000) “Flexible Sequence Similarity Searching with the FASTA3 Program Package”, Methods in Molecular Biology, 132: 185-219. [cited by applicant]
Pedersen et al. (1992) “Antibody Modeling: Beyond Homology”, Immunomethods, 1(2): 126-136. [cited by applicant]
Powell et al. (2011) “New Drug Targets for the Treatment of Obesity”, Clin. Pharmacol. Ther., 90(1): 40-51. [cited by applicant]
Raso et al. (1997) “Intracellular Targeting with Low pH-Triggered Bispecific Antibodies” J Biol Chem 272(44):27623-27628. [cited by applicant]
Rebouissou et al. (2009) “Frequent In-Frame Somatic Deletions Activate GP130 in Inflammatory Hepatocellular Tumours,” Nature, 457(7226): 200-205. [cited by applicant]
Reineke (2004) “Antibody Epitope Mapping Ussing Arrays of Synthetic Peptides,” Methods Mol. Biol., 248: 443-463. [cited by applicant]
Rhythm Pharma. Press Release, PRNewswire, Rhythm Presents Cardiovascular Safety Data from Phase 1b/2a Clinical Trials of Setmelanotide in Obesity (Nov. 6, 2015). [cited by applicant]
Savage et al. (2009) “Complement Abnormalities in Acquired Lipodystrophy Revisited”, J Clin Endocrinol Metab., 94(1): 10-16. [cited by applicant]
Segal et al. (2001) “Introduction: Bispecific Antibodies” J Immunol Meth., 248: 1-6. [cited by applicant]
Shetty et al. (2011) “Leptin Administration to Overweight and Obese Subjects for Six Months Increases Free Leptin Concentrations but Does not Alter Circulating Hormones of the Thyroid and IGF Axes During Weight Loss Ind… [cited by applicant]
Shields et al. (2002) “Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcγRIII and Antibody-dependent Cellular Toxicity”, JBC, 277: 26733-26740. [cited by applicant]
Smith et al. (1975) “Lipodystrophy, Pancreatitis, and Eosinophilia”, Gut., 16(3): 230-234. [cited by applicant]
States et al. (1991) “Improved Sensitivity of Nucleic Acid Database Searches Using Application-Specific Scoring Matrices”, Methods, 3: 66-70. [cited by applicant]
Stefater et al. (2012) “The Anorectic Effect of CNTF Does Not Require Action in Leptin-Responsive Neurons”, Endocrinology, 153(6): 2647-54. [cited by applicant]
Suthaus et al. (2010) “Forced Homo- and Heterodimerization of all gp 130-type Receptor Complexes Leads to Constitutive Ligand-Independent Signaling and Cytokine-Independent Growth”, Mol. Biol. Cell., 1(15): 2797-807. [cited by applicant]
Taga et al. (1997) “Gp130 and the interleukin-6 family of cytokines”, Annu. Rev. Immunol, 15: 797-819. [cited by applicant]
Tang et al. (1999) “Use of a Peptide Mimotope to Guide the Humanization of MRK-16, and Anti-P-Glycoprotein Monoclonal Antibody”, J Biol Chem., 274(39): 27371-27378. [cited by applicant]
Traunecker et al. (1991) “Bispecific Single Chain Molecules (Janusins) Target Cytotoxic Lymphocytes on HIV Infected Cells”, Embo J., 10(12): 3655-3659. [cited by applicant]
UK Working Party on Acute Pancreatitis (2005) “UK Guidelines for the Management of Acute Pancreatitis”, Gut.; 54 (Suppl 3): iii1-iii9. [cited by applicant]
Vajdos et al. (2002) “Comprehensive Functional Maps of the Antigen-binding Site of an Anti-ErbB2 Antibody Obtained with Shotgun Scanning Mutagenesis”, J. Mol. Biol., 320: 415-428. [cited by applicant]
Van Der Klaauw & Farooqi (2015) “The Hunger Genes: Pathways to Obesity”, Cell., 161(1): 119-132. [cited by applicant]
Van Maldergem et al. (2002) “Genotype-Phenotype Relationships in Berardinelli-Seip Congenital Lipodystrophy”, J Med Genet., 39(10): 722-733. [cited by applicant]
Vaughan et al. (1996) “Human Antibodies with Sub-Nanomolar Affinities Isolated from a Large Non-Immunized Phage Display Library”, Nat Biotechnol., 14: 309-314. [cited by applicant]
Villanueva and Myers (2008) “Leptin Receptor Signaling and the Regulation of Mammalian Physiology”, Int J Obes., 32: S8-S12. [cited by applicant]
Volkel et al. (2001) “Optimized Linker Sequences for the Expression of Monomeric and Dimeric Bispecific Single-Chain Diabodies”, Prot Eng. 14(10): 815-823. [cited by applicant]
Von Heijne (1983) “Patterns of Amino Acids Near Signal-Sequence Cleavage Sites”, Eur J Biochem., 133: 17-21. [cited by applicant]
Von Heijne (1986) “A New Method for Predicting Signal Sequence Cleavage Sites”, Nucl Acids Res., 14(11): 4683-4690. [cited by applicant]
Wikberg & Mutulis (2008) “Targeting Melanocortin Receptors: An Approach to Treat Weight Disorders and Sexual Dysfunction”, Nat Rev Drug Discov., 7(4): 307-323. [cited by applicant]
Wootton, et al. (1993) “Statistics of Local Complexity in Amino Acid Sequences and Sequence Databases”, Comput. Chem., 17:149-163. [cited by applicant]
Wren et al. (2002) “SIGNAL—Sequence Information and GeNomic AnaLysis”, Comp Meth Prog Biomed., 68: 177-181. [cited by applicant]
Wright et al. (2000) “Lymphoid/Neuronal Cell Surface OX2 Glycoprotein Recognizes a Novel Receptor on Macrophages Implicated in the Control of Their Function”, Immunity, 13: 233-242. [cited by applicant]
Wu et al. (1999) “Humanization of a Murine Monoclonal Antibody by Simultaneous Optimization of Framework and CDR Residues”, J. Mol. Biol., 294: 151-162. [cited by applicant]
Yiannias et al. (2006) “Peripheral T-Cell Lymphoma Presenting as Lipoatrophy and Nodules”, Int J Dermatol., 45(12): 1415-1419. [cited by applicant]
Zabeau et al. (2003) “The Ins and Outs of Leptin Receptor Activation”, FEBS Letters, 546: 45-50. [cited by applicant]
Zabeau et al. (2015) “Leptin: From Structural Insights to the Design of Antagonists”, Life Sciences, 140: 49-56. [cited by applicant]
Zadeh et al. (2013) “The Liver Diseases of Lipodystrophy: The Long-term Effect of Leptin Treatment”, J Hepatol., 59(1): 131-137. [cited by applicant]
Zhang et al. (1994) “Positional Cloning of the Mouse Obese Gene and Its Human Homologue”, Nature, 372: 425-432. [cited by applicant]
Zhang et al. (1997) “PowerBLAST: A New Network BLAST Application for Interactive or Automated Sequence Analysis and Annotation”, Genome Res., 7: 649-656. [cited by applicant]
Zhao et al. (2014) “Leptin and IL-6 Family Cytokines Synergize to Stimulate Müller Glia Reprogramming and Retina Regeneration,” Cell Reports, 9(1): 272-284. [cited by applicant]
Accession No. NP_002294.2. [cited by applicant]
Accession No. XP_005543194.1. [cited by applicant]
Ahmann, et al. (2015) “Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial,” Diabetes, … [cited by applicant]
Al-Lazikani et al., (1997) “Standard Conformations for the Canonical Structures of Immunoglobulins”, J. Mol. Biol. 273:927-948. [cited by applicant]
Allison, et al. (2014) “Connecting leptin signaling to biological function,” Journal of Endocrinology 223:T25-T35. [cited by applicant]
Altschul et al. (1990) “Basic Local Alignment Search Tool”, J. Mol. Biol. 215:403-410. [cited by applicant]
Altschul et al. (1997) “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs”, Nucleic Acids Res. 25:3389-402. [cited by applicant]
Al Qaraghuli, et al. (2020) “Antibody-Protein Binding and Conformational Changes: Identifying Allosteric Signaling Pathways to Engineer a Better Effector Response”, Nature Scientific Reports, 10:13969. [cited by applicant]
Bhaskar, et al. (2016) “An Allosteric Antibody to the Leptin Receptor Reduces Body Weight and Reverses the Diabetic Phenotype in the Lep [cited by applicant]
Bray and Wadden (2015) “Improving Long-Term Weight Loss Maintenance: Can We Do It?”, Obesity 23:2-3. [cited by applicant]
Carpenter et al. (2012) “Structure of the Human Obesity Receptor Leptin-Binding Domain Reveals the Mechanism of Leptin Antagonism by a Monoclonal Antibody”, Structure 20(3):487-497. [cited by applicant]
Chagnon et al. (2000) “Associations Between the Leptin Receptor Gene and Adiposity in Middle-Aged Caucasian Males from the HERITAGE Family Study”, Journal of Clinical Endocrinology & Metabolism 85(1):29-34. [cited by applicant]
Deddish et al. (1990) “Carboxypeptidase M in Madin-Darby Canine Kidney Cells” J. Biological Chemistry 265(25):15083-15089. [cited by applicant]
Edwards, et al. (2003) “The Remarkable Flexibility of the Human Antibody Repertoire; Isolation of Over One Thousand Different Antibodies to a Single Protein”, BLyS, Journal of Molecular Biology, 334:103-118. [cited by applicant]
Ehring (1999) “Hydrogen Exchange/Electrospray Ionization Mass Spectrometry Studies of Structural Features of Proteins and Protein/Protein Interactions” Analytical Biochemistry 267(2):252-259. [cited by applicant]
Engen and Smith (2001) The Basics of Ion Chromatography, Anal. Chem. 73:256A-265A. [cited by applicant]
Farooqi, et al. (2007) “Clinical and Molecular Genetic Spectrum of Congenital Deficiency of the Leptin Receptor,” N. Engl. J. Med. 356:237-247. [cited by applicant]
Farooqui, et al. (2002) “Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency,” The Journal of Clinical Investigation 110(8):… [cited by applicant]
Fazeli et al. (2006) “Identification of a monoclonal antibody against the leptin receptor that acts as an antagonist and blocks human monocyte and T cell activation”, J. Immunol. Methods 312:190-200. [cited by applicant]
Friedman (2014) “Leptin at 20: an overview”, J. Endocrinol. 223(1):T1-8. [cited by applicant]
Friedman and Halaas (1998) “Leptin and the regulation of body weight in mammals” Nature 395(6704):763-70. [cited by applicant]
Garg (2011) “Lipodystrophies: Genetic and Acquired Body Fat Disorders”, Journal of Clinical Endocrinology and Metabolism, 96(11):3313-3325. [cited by applicant]
Goel, et al. (2004) “Plasticity Within The Antigen-Combining Site May Manifest as Molecular Mimicry in the Humoral Immune Response”, J. Immunol., 173:7358-7367. [cited by applicant]
Gonnet et al. (1992) “Exhaustive Matching of the Entire Protein Sequence Database”, Science 256: 1443-1445. [cited by applicant]
Goodson (1984) in Medical Applications of Controlled Release, vol. 2, pp. 115-138. [cited by applicant]
Gorska, et al. (2010) “Leptin Receptors”, European Journal of Medical Research, 15(Supplemental II):50-54. [cited by applicant]
Haniu, et al. (1998) “Human Leptin Receptor, Determination of Disulfide Structure and N-Glycosylation Sites of the Extracellular Domain” J Biol Chem 273(44): 28691-69. [cited by applicant]
Halpern, et al. (2010) “Combinations of Drugs in the Treatment of Obesity”, Pharmaceuticals, 3:2398-2415. [cited by applicant]
Iepsen, et al. (2014) “Treatment With a GLP-1 Receptor Agonist Diminishes the Decrease in Free Plasma Leptin During Maintenance of Weight Loss,” International Journal of Obesity, 39(5):834-841. [cited by applicant]
Junghans et al. (1990) “Anti-Tac-H, a Humanized Antibody to the Interleukin 2 Receptor with New Features for Immunotherapy in Malignant and Immune Disorders”, Cancer Res. 50:1495-1502. [cited by applicant]
Justice, et al. (2016) “Using the Mouse to Model Human Disease: Increasing Validity and Reproducibility”, Disease, Models & Mechanisms 9:101-103. [cited by applicant]
Kazane et al., (2012) “Synthesis of Bispecific Antibodies using Genetically Encoded Unnatural Amino Acids”, J. Am. Chem. Soc., 134:9918-9921 [Epub: Dec. 4, 2012]. [cited by applicant]
Kazane, et al. (2013) “Self-Assembled Antibody Multimers through Peptide Nucleic Acid Conjugation,” Journal of the American Chemical Society, 135(1):340-346. [cited by applicant]
Khan, et al. (2014) “Adjustable Locks and Flexible Keys: Plasticity of Epitope-Paratope Interactions in Germline Antibodies”, J. Immunol. 192:5398-5405. [cited by applicant]
Klein et al. (2012) “Progress in overcoming the chain association issue in bispecific heterodimeric lgG antibodies”, mAbs 4:6, 653-663. [cited by applicant]
Kufer et al. (2004) “A revival of bispecific antibodies”, Trends Biotechnol. 22:239-244. [cited by applicant]
Langer (1990) “New Methods of Drug Delivery”, Science 249:1527-1533. [cited by applicant]
Li, et al. (2016) “The Role of Leptin in Central Nervous System Diseases”, NeuroReport 27(5):350-355. [cited by applicant]
Lin, et al. (2018) “Leptin signaling axis specifically associates with clinical prognosis and is multifunctional in regulating cancer progression”, Oncontarget 9(24):17210-17219. [cited by applicant]
Mancour, et al. (2012) “Ligand-Induced Architecture of the Leptin Receptor Signaling Complex,” Molecular Cell 48:655-661. [cited by applicant]
Marcic et al. (2000) “Replacement of the Transmembrane Anchor in Angiotensin I-converting Enzyme (ACE) with a Glycosylphosphatidylinositol Tail Affects Activation of the B [cited by applicant]
Mak, et al. (2014) “Exploiting the therapeutic potential of leptin signaling in cachexia”, Current Opinion in Supportive and Palliative Care 8(4):352-357. [cited by applicant]
Martin et al., (1989) “Modeling antibody hypervariable loops: A combined algorithm”, Proc. Natl. Acad. Sci. USA 86:9268-9272. [cited by applicant]
Mayo Clinic (2015) “Lipodystrophy Syndromes: New Treatment, Newer Questions”, Published online Sep. 1, 2015, 4 pages. [cited by applicant]
Mazen, et al. (2011) “Homozygosity for a Novel Missense Mutation in the Leptin Receptor Gene (P316T) in two Egyptian Cousins with Severe Early Onset Obesity,” Molecular Genetics and Metabolism, 102:461-464. [cited by applicant]
McMurphy et al., (2014) “The Anti-Tumor Activity of a Neutralizing Nanobody Targeting Leptin Receptor in a Mouse Model of Melanoma”, PLOS One (2014) 9(2):e89895. [cited by applicant]
Meehan, et al. (2016) “Metreleptin for Injection to Treat the Complications of Leptin Efficiency in Patients with Congenital or Acquired Generalized Lipodystrophy,” Clinical Pharmacology 9(1):59-68. [cited by applicant]
Molek, et al. ( 2014) “Screening of synthetic phage display scFv libraries yields competitive ligands of human leptin receptor”, Biochemical and Biophysical Research Communications 452(3):479-483. [cited by applicant]
Moon et al. (2013) “Leptin's Role in Lipodystrophic and Nonlipodystrophic Insulin-Resistant and Diabetic Individuals”, Endocrine Reviews, 34(3):377-412. [cited by applicant]
Mordenti et al. (1991) “Interspecies Scaling of Clearance and Volume of Distribution Data for Five Therapeutic Proteins”, Pharmaceut. Res. 8:1351. [cited by applicant]
Morris, et al. (1996) “Epitope Mapping of Protein Antigens by Competition ELISA”, The Protein Protocols Handbook, Humana Press, pp. 595-600. [cited by applicant]
Osorio (2014) “Leptin and Leptin Receptor Expressions in Prostate Tumors May Predict Disease Aggressiveness?”, Acta Cirurgica Brasileira, 29(supl.3), 5pages. [cited by applicant]
Padlan (1994) “Anatomy of the Antibody Molecule”, Molecular Immunology, 31(3):169-217. [cited by applicant]
Park and Ahima (2014) “Leptin Signaling”, F1000Prime Reports, 73(6), 8 pages. [cited by applicant]
Paz-Filho, et al. (2014) “Leptin treatment: Facts and expectations,” Metabolism, pp. 1-11, http://dx.doi.org/10.1016/j.metabol.2014.07.014. [cited by applicant]
Phillips (2001) “The Challenge of Gene Therapy and DNA Delivery”, J. Pharm. Pharmacology 53:1169-1174. [cited by applicant]
International Search Report and Written Opinion received for PCT/US2017/060690 on Jan. 10, 2018, 17 pages. [cited by applicant]
PCT International Search Report and Written Opinion received for PCT/US2016/056465, on Jan. 10, 2017. [cited by applicant]
Pearson (1994) “Using the FASTA Program to Search Protein and DNA Sequence Databases”, Methods Mol. Biol. 24: 307-331. [cited by applicant]
Peelman, et al. (2014) “Insights into signaling assemblies of the leptin receptor,” Journal of Endocrinology 223:T9-T23. [cited by applicant]
Poosarla, et al. (2017) “Computational De Novo Design of Antibodies Binding to a Peptide With High Affinity”, Biotechn. Bioeng., 114(6):1331-1342. [cited by applicant]
Powell et al. (1998) “Compendium of excipients for parenteral formulations” PDA (1998) J. Pharm. Sci. Technol. 52:238-311. [cited by applicant]
Procaccini, et al. (2015) “Leptin in autoimmune diseases,” Metabolism Clinical and Experimental 64:92-104. [cited by applicant]
Rabia, et al. (2018) “Understanding and Overcoming Trade-Offs Between Antibody Affinity, Specificity, Stability and Solubility,” Biochemical Engineer Journal, 137:365-374. [cited by applicant]
Reddy et al., (2000) “Elimination of Fc Receptor-Dependent Effector Functions of a Modified IgG4 Monoclonal Antibody to Human CD4”, J. Immunol. 164:1925-1933. [cited by applicant]
Rosenbaum, et al. (2002) “Low Dose Leptin Administration Reverse Effects of Sustained Weight-Reduction on Energy Expenditure and Circulating Concentrations of Thyroid Hormones,” The Journal of Clinical Endocrinology & M… [cited by applicant]
Rosenbaum, et al. (2005) “Low-dose Leptin Reverses Skeletal Muscle, Autonomic, and Neuroendocrine Adaptations to Maintenance of Reduced Weight” The Journal of Clinical Investigation 115(12):3579-3586. [cited by applicant]
Sefton (1987) “Implantable Pumps”, CRC Crit. Ref. Biomed. Eng. 14:201-240. [cited by applicant]
Shimomura, et al. (1999) “Leptin Reverses Insulin Resistance and Diabetes Mellitus in Mice with Congenital Lipodystrophy,” Nature 401:73-76. [cited by applicant]
Sinha, et al. (1996) “Evidence of Free and Bound Leptin in Human Circulation,” The Journal of Clinical Investigation 98(6):1277-1282. [cited by applicant]
Sweeney (2002) “Leptin signalling”, Cell Signal 14(8):655-663. [cited by applicant]
Tartaglia et al., (1995) “Identification and Expression Cloning of a Leptin Receptor, OB-R”, Cell, 83(7):1263-1271. [cited by applicant]
Tartaglia (1997) “The Leptin Receptor”, J. Biol. Chem 7:272(10):6093-6096. [cited by applicant]
Taylor et al. (1992) “A transgenic mouse that expresses a diversity of human sequence heavy and light chain immunoglobulins”, Nucl. Acids Res. 20:6287-6295. [cited by applicant]
Tomer (2000) “Characterization of a discontinuous epitope of the human immunodeficiency virus (HIV) core protein p24 by epitope excision and differential chemical modification followed by mass spectrometric peptide mapp… [cited by applicant]
Tutt et al. (1991) “Trispecific F(ab′) [cited by applicant]
University of Utah Healthcare (2014) “Knowing the Difference Between Inherited and Acquired Cancers Can Save Lives”, Published online Sep. 5, 2014, 3 pages. [cited by applicant]
Ussar, et al. (2011) “Receptor Antibodies as Novel Therapeutics for Diabetes,” Science Translational Medicine, 3(113):22-24. [cited by applicant]
Wauman, et al. (2011) “Leptin Receptor Signaling: Pathways to Leptin Resistance”, Frontiers in Biosciences 16:2771-2793. [cited by applicant]
Wu et al. (1987) “Receptor-mediated in Vitro Gene Transformation by a Soluble DNA Carrier System”, J. Biol. Chem. 262:4429-4432. [cited by applicant]
Zabeau et al. (2014) “Antagonizing leptin: current status and future directions” Biol. Chem. 395(5):499-514. [cited by applicant]
Akinci, et al. (2018) “Update on Therapeutic Options in Lipodystrophy,” Current Diabetes Reports 18 :139, pp. 1-12. [cited by applicant]
Kawaji, et al. (2001) “Anti-leptin Receptor Antibody Mimics the Stimulation of Lipolysis Induced by Leptin in Isolated Mouse Fat Pads”, Journal of Lipid Research, 42(10):1671-1677. [cited by applicant]
Molina, et al. (2014) “Pressure Ulcers—Burns/Annals of Physical Rehavilitation Medicine,” Lipoatrophia Semicircularis: A case report Abstract P159-e, 57S : e212-e217. [cited by applicant]
Nolis (2014) “Exploring the Pathophysicology Behind the More Common Genetic and Acquired Lipodystrophies,” Journal of Human Genetics, 59 : 16-23. [cited by applicant]
Purdham, et al. (2007) “A Neutralizing Leptin Receptor Antibody Mitigates Hypertrophy and Hemodynamic Dysfunction in the Postinfarcted Rat Heart”, Am. J. Physiol, Heart Circ. Physiol., 295(1):H441-H446. [cited by applicant]
Stears, et al. (2014) “Diagnosis and Management of Lipodystrophy: a Practical Update,” Clinical Lipidology, 9(2): 235-259. [cited by applicant]
2008 Guidance Document “Ethical Considerations for Clinical Trials on Medicinal Products Conducted with the Pediatric Population”. [cited by applicant]
Addy et al. (2008) “Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of Taranabant, a Novel Selective Cannabinoid-1 Receptor Inverse Agonist, for the Treatment of Obesity: Results from a Double-bli… [cited by applicant]
Aijluni (2017) “Efficacy and Safety of Metreleptin in Patients with Partial Lipodystrophy: Lessons from an Expanded Access Program,” Journal of Diabetes & Metabolism, 7(3): 1000659, 7 pages. [cited by applicant]
Al-Attar et al. (2007) “Quantitative and Qualitative Differences in Subcutaneous Adipose Tissue Stores Across Lipodystrophy Types Shown by Magnetic Resonance Imaging,” BMC Med Imaging, 7: 3. [cited by applicant]
Allen, Loyd V. Jr. Ph.D. “The Art, Science and Technology of Pharmaceutical Compounding,” in American Pharmacists Association (Washington, D.C., 1999), Introduction pages xxxii-xxxvii. [cited by applicant]
Angrisani et al. (2017) “Bariatric Surgery and Endoluminal Procedures: IFSO Worldwide Survey 2014,” Obes Surg., 27(9): 2279-2289. [cited by applicant]